Orchestra BioMed (OBIO) Competitors $2.44 -0.62 (-20.26%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.47 +0.03 (+1.23%) As of 08/1/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OBIO vs. BVS, ZIMV, BFLY, DCTH, TMCI, RXST, OM, SNWV, CLPT, and STIMShould you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include Bioventus (BVS), ZimVie (ZIMV), Butterfly Network (BFLY), Delcath Systems (DCTH), Treace Medical Concepts (TMCI), RxSight (RXST), Outset Medical (OM), Sanuwave Health (SNWV), ClearPoint Neuro (CLPT), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry. Orchestra BioMed vs. Its Competitors Bioventus ZimVie Butterfly Network Delcath Systems Treace Medical Concepts RxSight Outset Medical Sanuwave Health ClearPoint Neuro Neuronetics Bioventus (NASDAQ:BVS) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation. Which has preferable earnings & valuation, BVS or OBIO? Bioventus has higher revenue and earnings than Orchestra BioMed. Bioventus is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioventus$573.28M0.89-$33.54M-$0.48-12.88Orchestra BioMed$2.64M35.41-$61.02M-$1.78-1.37 Do analysts rate BVS or OBIO? Orchestra BioMed has a consensus price target of $14.00, suggesting a potential upside of 473.77%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Bioventus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventus 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Orchestra BioMed 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media prefer BVS or OBIO? In the previous week, Orchestra BioMed had 4 more articles in the media than Bioventus. MarketBeat recorded 4 mentions for Orchestra BioMed and 0 mentions for Bioventus. Orchestra BioMed's average media sentiment score of 0.52 beat Bioventus' score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the news media. Company Overall Sentiment Bioventus Neutral Orchestra BioMed Positive Which has more volatility and risk, BVS or OBIO? Bioventus has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Is BVS or OBIO more profitable? Bioventus has a net margin of -5.57% compared to Orchestra BioMed's net margin of -2,297.85%. Bioventus' return on equity of 21.47% beat Orchestra BioMed's return on equity.Company Net Margins Return on Equity Return on Assets Bioventus-5.57% 21.47% 5.38% Orchestra BioMed -2,297.85%-189.26%-93.76% Do insiders & institutionals hold more shares of BVS or OBIO? 62.9% of Bioventus shares are owned by institutional investors. Comparatively, 53.6% of Orchestra BioMed shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Comparatively, 8.1% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryBioventus beats Orchestra BioMed on 9 of the 17 factors compared between the two stocks. Get Orchestra BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBIO vs. The Competition Export to ExcelMetricOrchestra BioMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$117.24M$2.99B$5.48B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.3717.7428.8623.83Price / Sales35.41178.75371.7266.14Price / CashN/A41.9535.4557.96Price / Book2.808.508.275.54Net Income-$61.02M-$55.06M$3.25B$259.28M7 Day Performance-25.84%-3.99%-3.74%-4.67%1 Month Performance-15.28%9.58%4.28%4.37%1 Year Performance-63.80%6.70%25.87%17.91% Orchestra BioMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBIOOrchestra BioMed2.4418 of 5 stars$2.44-20.3%$14.00+473.8%-64.4%$117.24M$2.64M-1.374News CoverageGap DownHigh Trading VolumeBVSBioventus1.0087 of 5 stars$6.51-0.3%N/AN/A$534.73M$573.28M-13.561,200ZIMVZimVie0.9382 of 5 stars$18.82flat$17.00-9.7%-8.0%$523.86M$449.75M-26.491,770News CoverageEarnings ReportUpcoming EarningsAnalyst DowngradeBFLYButterfly Network2.4384 of 5 stars$1.94-0.3%$3.50+80.9%+36.9%$476.03M$85.63M-6.64460Trending NewsAnalyst DowngradeGap DownDCTHDelcath Systems2.7068 of 5 stars$11.32-0.8%$24.00+112.0%+29.3%$396.04M$53.85M-22.7460Upcoming EarningsAnalyst UpgradeTMCITreace Medical Concepts2.4138 of 5 stars$5.72-0.5%$10.52+83.7%-19.0%$359.42M$209.36M-6.72250News CoveragePositive NewsUpcoming EarningsRXSTRxSight3.3687 of 5 stars$7.94+0.8%$17.50+120.5%-82.4%$322.07M$139.93M-11.83220Trending NewsUpcoming EarningsOMOutset Medical1.7102 of 5 stars$18.01-0.1%$29.50+63.8%-71.4%$319.07M$115.27M-0.62520Upcoming EarningsSNWVSanuwave Health2.2821 of 5 stars$36.48+2.0%$49.00+34.3%N/A$312.63M$32.63M-8.0140News CoverageAnalyst ForecastAnalyst RevisionCLPTClearPoint Neuro2.6744 of 5 stars$10.90-0.7%$25.00+129.5%+47.1%$305.44M$32.24M-14.36110Analyst ForecastGap DownSTIMNeuronetics1.5458 of 5 stars$4.54+0.4%$5.50+21.2%+148.3%$301.00M$74.89M-3.48180Upcoming EarningsGap Down Related Companies and Tools Related Companies BVS Competitors ZIMV Competitors BFLY Competitors DCTH Competitors TMCI Competitors RXST Competitors OM Competitors SNWV Competitors CLPT Competitors STIM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBIO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchestra BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
